DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

被引：0
|
作者：
Gambardella, Valentina
Greystoke, Alastair
Reck, Martin
Liu, Meiruo
Mueller, Martha
Duenzinger, Ulrich
Bergsland, Emily B.
Owonikoko, Taofeek
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-LB_A16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB_A16
引用
收藏
页数：2
相关论文
共 50 条
  • [41] BISPECIFIC T-CELL ENGAGER (BITE®) ANTIBODY BLINATUMOMAB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN OPEN-LABEL PHASE 2 STUDY
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    HAEMATOLOGICA, 2014, 99 : 154 - 154
  • [42] Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
    Krebs, Matthew G.
    Delord, Jean-Pierre
    Evans, Thomas R. Jeffry
    De Jonge, Maja
    Kim, Sang-We
    Meurer, Marie
    Postel-Vinay, Sophie
    Lee, Jong-Seok
    Angell, Helen K.
    Rocher-Ros, Vidalba
    Meyer, Kassondra
    Ah-See, Mei-Lin
    Herbolsheimer, Pia
    Lai, Zhongwu
    Nunes, Ana
    Domchek, Susan M.
    LUNG CANCER, 2023, 180
  • [43] An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC)
    Gandhi, L.
    Chu, Q. S.
    Stephenson, J.
    Johnson, B. E.
    Govindan, R.
    Bonomi, P.
    Eaton, K.
    Fritsch, H.
    Munzert, G.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Jamie E. Chaft
    Filiz Oezkan
    Mark G. Kris
    Paul A. Bunn
    Ignacio I. Wistuba
    David J. Kwiatkowski
    Dwight H. Owen
    Yan Tang
    Bruce E. Johnson
    Jay M. Lee
    Gerard Lozanski
    Maciej Pietrzak
    Michal Seweryn
    Woo Yul Byun
    Katja Schulze
    Alan Nicholas
    Ann Johnson
    Jessica Grindheim
    Stephanie Hilz
    David S. Shames
    Chris Rivard
    Eric Toloza
    Eric B. Haura
    Ciaran J. McNamee
    G. Alexander Patterson
    Saiama N. Waqar
    Valerie W. Rusch
    David P. Carbone
    Nature Medicine, 2022, 28 : 2155 - 2161
  • [45] Erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC): Results of a phase II open-label trial
    Piantedosi, F., V
    Gilli, M.
    Caputo, F.
    Casale, B.
    Bianco, A.
    Dericoloso, A.
    Pontillo, A.
    Crispino, C.
    Giuliarini, G.
    Hengheller, M.
    Chianca, P.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 26
  • [46] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Chaft, Jamie E.
    Oezkan, Filiz
    Kris, Mark G.
    Bunn, Paul A.
    Wistuba, Ignacio I.
    Kwiatkowski, David J.
    Owen, Dwight H.
    Tang, Yan
    Johnson, Bruce E.
    Lee, Jay M.
    Lozanski, Gerard
    Pietrzak, Maciej
    Seweryn, Michal
    Byun, Woo Yul
    Schulze, Katja
    Nicholas, Alan
    Johnson, Ann
    Grindheim, Jessica
    Hilz, Stephanie
    Shames, David S.
    Rivard, Chris
    Toloza, Eric
    Haura, Eric B.
    McNamee, Ciaran J.
    Patterson, G. Alexander
    Waqar, Saiama N.
    Rusch, Valerie W.
    Carbone, David P.
    NATURE MEDICINE, 2022, 28 (10) : 2155 - +
  • [47] An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
    Xie, Y.
    Mi, L.
    Zheng, W.
    Ping, L.
    Lin, N.
    Tu, M.
    Zhang, C.
    Ying, Z.
    Liu, W.
    Deng, L.
    Wu, M.
    Wang, X.
    Zhu, J.
    Song, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
  • [48] Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
    Aix, Santiago Ponce
    Ciuleanu, Tudor Eliade
    Navarro, Alejandro
    Cousin, Sophie
    Bonanno, Laura
    Smit, Egbert F.
    Chiappori, Alberto
    Olmedo, Maria Eugenia
    Horvath, Ildiko
    Grohe, Christian
    Farago, Anna F.
    Lopez-Vilarino, Jose Antonio
    Cullell-Young, Martin
    Nieto, Antonio
    Vasco, Noelia
    Gomez, Javier
    Kahatt, Carmen
    Zeaiter, Ali
    Carcereny, Enric
    Roubec, Jaromir
    Syrigos, Konstantinos
    Lo, Gregory
    Barneto, Isidoro
    Pope, Anthony
    Sanchez, Amparo
    Kattan, Joseph
    Zarogoulidis, Konstantinos
    Waller, Cornelius F.
    Bischoff, Helge
    Juan-Vidal, Oscar
    Reinmuth, Niels
    Domine, Manuel
    Paz-Ares, Luis
    LANCET RESPIRATORY MEDICINE, 2023, 11 (01): : 74 - 86
  • [49] Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
    Smit, Marie-Anne Damiette
    Borghaei, Hossein
    Owonikoko, Taofeek Kunle
    Hummel, Horst-Dieter
    Johnson, Melissa Lynne
    Champiat, Stephane
    Salgia, Ravi
    Udagawa, Hibiki
    Boyer, Michael J.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] PROLONGED ADMINISTRATION OF ORAL ETOPOSIDE IN PATIENTS WITH RELAPSED OR REFRACTORY SMALL-CELL LUNG-CANCER - A PHASE-II TRIAL
    JOHNSON, DH
    GRECO, FA
    STRUPP, J
    HANDE, KR
    HAINSWORTH, JD
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) : 1613 - 1617
12345